PRS2
PRESCRIPTION PATTERNS IN COPD PATIENTS IN A GERMAN SICKNESS FUND POPULATION
Gotha H1, Sandtmann R2, Hoeer A1, Schiﬀhorst G1, Storz P1, Glaeske G1, Haeussler B1
1IGES, Berlin, Germany; 2ALTANA Pharma AG, Konstanz, Germany; 3University of Bremen, Bremen, Germany
OBJECTIVES: To investigate into the prescription patterns of COPD patients. METHODS: Rx claims data were analyzed for the period from 2001 to 2003. COPD patients were selected from claims data, if they were at least 45 years of age and had at least one diagnosis of COPD or emphysema (ICD-10 J43 and J44) and/or one Rx of a drug for obstructive airway diseases (ATC code R03) and had no indications of an allergic disease (e.g., Rx of antihistamines). The percentage of beneficiaries with defined Rx patterns (e.g., combination of bronchodilators) was analyzed per quarter starting with the quarter of inclusion of each beneficiary. RESULTS: 34,440 COPD patients were selected, of whom 28,769 received prescriptions of the predefined drug classes. Inhaled corticosteroids (ICS) and short acting beta agonists were prescribed to most of the beneficiaries (42.8 and 40.1%, resp., within three years). Regarding the prescription patterns in quarterly periods, ICS and long acting bronchodilators were identiﬁed as being the most often prescribed combination (up to 19% of the beneﬁciaries) followed by long acting bronchodilators (up to 11% of the beneﬁciaries). Strikingly, the percentage of beneficiaries without any Rx of a drug for obstructive airway diseases was very high. In patients selected by diagnosis, the percentage of beneficiaries without medication varied between 29 and 57%, whereas for those selected exclusively by drug Rx the percentage ranged from 45 to 71%. CONCLUSION: Our findings demonstrate that the beneﬁciaries receive prescriptions for long acting bronchodilators and ICS, either as mono or as combination therapy. In many cases of COPD, however, there is no long-term drug treatment. Further research should ﬁnd out whether this means adequate treatment, regarding the different severity levels of the disease, or indicates insufﬁcient therapy.

PRS3
COST ANALYSIS OF FOUR TREATMENT STRATEGIES IN THE MANAGEMENT OF MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE: AN APPLICATION ON NON-PARAMETRIC BOOTSTRAP
Fattor A1, Torbica A1, Mangone M2
1Bocconi University, Milano, Mi, Italy; 2AstraZeneca S.p.a, Basiglio, Milan, Italy
OBJECTIVES: To evaluate and compare direct health care costs associated with four alternative treatment strategies used in patients with moderate-to-severe chronic obstructive pulmonary disease in Italy. METHODS: Data on resource consumption were collected alongside 12-month, multinational, randomised, double-blind, placebo-controlled trial that compared four treatment strategies: budesonide/formoterol combination in a single inhaler, budesonide as a single therapy, formoterol as a single therapy and placebo. Economic analysis was conducted on patients from 6 European countries. The prospective was that of Italian NHS; national charges and prices were used to evaluate resource consumption. Average total cost per patient per year and its confidence intervals was assessed in each group with bootstrap percentile method. Differences between groups were tested with bootstrap-Z method. RESULTS: Overall sample included 272 patients (mean age = 65.3 years) equally distributed in four treatment groups. The patients treated with budesonide/formoterol combination in a single inhaler tended to consume less health care resources in terms of hospital days and emergency room visits than patients treated with single drugs. Average total cost per patient per year was €1763 in group treated with budesonide/formoterol combination in a single inhaler, €1436 in budesonide group and €2725 in the formoterol group. There was no statistically signiﬁcant difference between the alternative treatment strategies. CONCLUSION: Present costs analysis suggests that its introduction in the management of patients with moderate-to-severe chronic obstructive disease doesn’t increment consumption of health care resources when compared to single drug alternatives.

PRS4
INHALED CORTICOSTEROIDS AND BROCHODILATORS FOR SEVERE AND VERY SEVERE COPD PATIENTS: COST-EFFECTIVENESS AND HEALTH CARE BUDGET IMPACT IN ITALY
Pradelli L1, Iannazzo S1, Dal Negro JW2, Eandi M3
1Advanced Research Srl, Torino, Italy; 2ASL 22, Bussolengo (VR), Italy; 3University of Turin, Torino, Italy
METHODS: Published data on the Italian COPD population were fitted in a disease progression model based on a Markov chain representing severity stages and death. Alternative therapeutic options (salmeterol/fluticasone—S/F—formoterol/budesonide—F/B—salmeterol alone—S—fluticasone alone—F—and control—C) were represented as competing arms in a decision tree. Efficacy data from international trials were expressed in terms of risk reduction. Clinical parameters used were number of exacerbations and symptom-free days. Direct and indirect costs were considered and valued according to current prices and tariffs. Analyses were conducted from Italian National Health Service, societal and patient perspectives with time horizons of 1, 5, and 10 years and life-long. RESULTS: The yearly total direct cost of treating COPD patients in Italy is estimated in approximately €7 billion, with a mean cost/patient/year around €2450. Mean survival of the cohort is 11.3 years. The C and F strategies are dominated (i.e. are associated with worse outcomes and higher costs) by all alternatives. S/F and F/B are the most effective strategies, with a slight clinical superiority of S/F, but they are also marginally more expensive than S. Incremental cost/effectiveness of S/F vs. S is €679.5/avoided exacerbation and 3.3 Euro/symptom-free day. CONCLUSIONS: The recommended use of combined inhaled corticosteroids and long-acting bronchodilators for severe and very severe COPD patients, as compared with current practice, has the potential of improving clinical outcomes without increasing health care costs.

PRS5
PHARMAECONOMIC EVALUATION OF TIOTROPIUM IN THE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN SPAIN
De Lucas P1, Rodríguez JM2, Gobarts E1, Soto I1, Martin A1
1Gregorio Marañón Hospital, Madrid, Spain; 2Gregorio Marañón Hospital, Madrid, Madrid, Spain; 3Boehringer Ingelheim Spain, Sant Cugat del Valles, Barcelona, Spain; 4Pfizer Spain, Alcobendas, Madrid, Spain
OBJECTIVES: Chronic obstructive pulmonary disease (COPD) has a prevalence of 9.1% in Spain. Exacerbation is one of the